{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:22Z","timestamp":1788412462437,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Zenagamtide is a novel, unimolecular glucagon\u2010like peptide\u20101 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Adults with body mass index 20.0\u201339.9\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      were categorised based on baseline renal status using the CKD\u2010EPI Collaboration creatinine equation (2021); normal function, mild impairment, moderate impairment, severe impairment and end\u2010stage renal disease (ESRD). Participants received a single subcutaneous dose of zenagamtide 0.3\u2009mg, followed by a 4\u2010week follow\u2010up period. The primary endpoint was area under the zenagamtide plasma concentration\u2013time curve from time zero to infinity (AUC\n                      <jats:sub>0\u2013\u221e<\/jats:sub>\n                      ). Additional endpoints included maximum observed plasma zenagamtide concentration (\n                      <jats:italic>C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      ) and number of treatment\u2010emergent adverse events (TEAEs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 42 participants were included (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914, normal renal function group;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097 per renal impairment group). The range (geometric mean) of zenagamtide AUC\n                      <jats:sub>0\u2013\u221e<\/jats:sub>\n                      and\n                      <jats:italic>C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      across renal impairment groups were 520\u2013715\u2009h\u2009\u00d7\u2009nmol\/L and 2.8\u20133.5\u2009nmol versus 543\u2009h\u2009\u00d7\u2009nmol\/L and 3.2\u2009nmol\/L for the normal renal function group, respectively. Overall, TEAEs were reported in 30 (71.4%) participants. TEAEs were non\u2010serious, none were severe and the majority were mild and most frequently gastrointestinal in nature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Renal impairment did not appear to have a clinically relevant impact on the PK or safety profile of zenagamtide, suggesting that dose adjustment of zenagamtide is not warranted in this population.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      : NCT06559527.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71096","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:56:08Z","timestamp":1783997768000},"page":"8946-8954","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide"],"prefix":"10.1111","volume":"28","author":[{"given":"Lykke Ida Kaas","family":"Oldenburg","sequence":"first","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sine Pfeiffer","family":"Haugaard","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Kegel\u2010H\u00fcbner","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Research Organisation GmbH  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahera","family":"Parwez","sequence":"additional","affiliation":[{"name":"Novo Nordisk Global Business Services  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Wiingaard","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Flint","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab848"},{"key":"e_1_2_10_3_1","volume-title":"Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation","author":"World Health Organization","year":"1999"},{"issue":"1","key":"e_1_2_10_4_1","first-page":"49","article-title":"Diabetic Kidney Disease: World Wide Difference of Prevalence and Risk Factors","volume":"5","author":"Gheith O.","year":"2016","journal-title":"Journal of Nephropharmacology"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2012.10.010"},{"issue":"9","key":"e_1_2_10_6_1","article-title":"Obesity\u2010Related Kidney Disease: Current Understanding and Future Perspectives","volume":"11","author":"Kreiner F. F.","year":"2023","journal-title":"Biomedicine"},{"key":"e_1_2_10_7_1","unstructured":"European Medicines Agency \u201cGuideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Decreased Renal Function (EMA\/CHMP\/83874\/2014) \u201d(2015) https:\/\/www.ema.europa.eu\/en\/evaluation\u2010pharmacokinetics\u2010medicinal\u2010products\u2010patients\u2010decreased\u2010renal\u2010function\u2010scientific\u2010guideline."},{"key":"e_1_2_10_8_1","unstructured":"Food and Drug Administration CfDEaR \u201cPharmacokinetics in Patients with Impaired Renal Function\u2014Study Design Data Analysis and Impact on Dosing. Guidance for Industry \u201d(2024) https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/pharmacokinetics\u2010patients\u2010impaired\u2010renal\u2010function\u2010study\u2010design\u2010data\u2010analysis\u2010and\u2010impact\u2010dosing."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpmed.2023.10.009"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310449"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00243-1"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01751-7"},{"key":"e_1_2_10_17_1","unstructured":"Food and Drug Administration CfDEaR \u201cSYMLIN (Pramlintide Acetate) Prescribing Information \u201d(2019) accessed December 2 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021332s028lbl.pdf."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010026\u201001654\u20100"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0528-2"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01012-2"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30268-7"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03015-5"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0472"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01185-7"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01176-6"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14487"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00845-X"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0144"},{"key":"e_1_2_10_32_1","unstructured":"National Kidney Foundation \u201cCKD\u2010EPI Creatinine Equation (2021) \u201d(2021) accessed November 26 2025 https:\/\/www.kidney.org\/ckd\u2010epi\u2010creatinine\u2010equation\u20102021\u20100."},{"issue":"5","key":"e_1_2_10_33_1","first-page":"303","article-title":"A Formula to Estimate the Approximate Surface Area if Height and Weight Be Known. 1916","volume":"5","author":"Du Bois D.","year":"1989","journal-title":"Nutrition"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.020"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2023\u20106\u20101"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12374"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01198-5"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v14.i1.101917"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261926"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71096","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71096","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:21:09Z","timestamp":1788409269000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/dom.71096"],"URL":"https:\/\/doi.org\/10.1111\/dom.71096","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"2026-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}